All stock lists
Td Synnex Corp (New York Stock Exchange:SNX)
US · Delayed Price · Currency is USD
Technology · Technology Distributors
252.28+4.94 (+2.00%)
Insider Score
––Not scored
SNX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
SNX analyst forecast
SNX analyst consensus
Moderate Buy3 ratings
Buy 2 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
SNX 12-month price target
$341.67+35.0% upsideaverage of 3 firms
$379.00High
$287.00Low
Best analysts covering SNX
- RBC Capital100%success rate · 8 calls
- Morgan Stanley100%success rate · 3 calls
- Goldman Sachs100%success rate · 3 calls
- Barrington Research88%success rate · 17 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
SNX analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Morgan Stanley | Overweight | $359.00 | +38.4% | Reiterated | 2026-09-25 | |
| UBS | Buy | $379.00 | +40.9% | Reiterated | 2026-09-25 | |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-09-15 |
| Barclays | Equal Weight | $287.00 | +9.3% | Reiterated | 2026-09-08 | |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-07-02 |
| — | UBS | Buy | — | — | Reiterated | 2026-06-26 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-06-26 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-06-26 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-06-23 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-06-16 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2026-06-12 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-06-10 |
| — | UBS | Buy | — | — | Reiterated | 2026-06-09 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-05-29 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2026-05-27 |
| — | UBS | Buy | — | — | Reiterated | 2026-05-05 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-04-30 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-04-22 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-04-16 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2026-04-02 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-04-01 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-04-01 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-04-01 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-04-01 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-03-27 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-03-20 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-01-09 |
| — | UBS | Buy | — | — | Reiterated | 2026-01-09 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-01-09 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-01-09 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-12-17 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-09-29 |
| — | UBS | Buy | — | — | Reiterated | 2025-09-29 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-09-26 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-09-26 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-09-26 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-09-26 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-09-26 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-09-23 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-09-18 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-08-22 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-07-24 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-07-17 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-07-11 |
| — | Loop Capital | Buy | — | — | Reiterated | 2025-06-30 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-06-25 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-06-25 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-06-23 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-04-11 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-04-11 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-04-11 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-03-28 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-03-28 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-03-28 |
| — | UBS | Buy | — | — | Reiterated | 2025-03-28 |
| — | CFRA | Buy | — | — | Reiterated | 2025-03-28 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-03-28 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-03-20 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-02-21 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-01-15 |
SNX earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-31 | 3.29 | 4.73 | $15.59B | $17.16B |
| 2026-06-25 | 4.14 | 4.85 | $16.80B | $19.57B |
| 2026-09-24 | 4.70 | 5.68 | $18.91B | $21.56B |
| 2027-01-14 | 5.95 | 0.00 | $22.24B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.